Home › Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
 

Keywords :   


Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)

2016-07-25 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced two regulatory milestones for the companys investigational vaccine for Ebola Zaire, V920 (rVSVG-ZEBOV-GP, live attenuated): the U.S. Food and Drug Administration (FDA) has granted the vaccine candidate Breakthrough Therapy Designation, and the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) status. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: status prime therapy receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Bell adds 14,174 net retail IPTV subscribers in 1Q 2024
13.05IT Cosmetics Revamps CC Cream & Adds Sun Blush for Spring 2024
13.05Lottie London Teams with Netflix for Endless Summer Cosmetics Collection
13.05Meat prices expected to increase slightly this summer
13.05Innovia launches hot melt barrier film for fridge and freezer labels
13.05Pennsylvania law aims to protect domestic animals, food supply against disease
13.05Ongoing influenza A surveillance critical for U.S. swine herd health
13.05Warning over 'disastrous' BBC podcast advert plan
More »